key: cord-0767855-2yo8hyja
authors: Adir, Yochai; Humbert, Marc; Saliba, Walid
title: COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids : nationwide real-world evidence
date: 2021-06-15
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.06.006
sha: a47d1c7594be67800bdfc1eec3d451c95772d1a2
doc_id: 767855
cord_uid: 2yo8hyja

Background Managing severe asthma during the SARS-CoV-2 pandemic is challenging, particularly due to safety concerns regarding the use of systemic corticosteroids and biologics. Objectives To determine the association between biologics or systemic corticosteroids use with PCR positivity for SARS-CoV-2 and COVID-19 outcomes among asthmatic patients Methods We used the computerized database of Clalit Health Services, the largest healthcare provider in Israel, to identify all asthmatic adult patients who underwent PCR testing for SARS-CoV-2, between 1st of March 2020 and 7th December 2020. A cohort approach was used to assess the association between biologics use and steroids treatment and COVID-19 severity and 90-day mortality. Results Overall, 8,242 out of 80,602 tested asthmatics had positive PCR testing for SARS-CoV-2. Both biologics and systemic corticosteroids were not associated with increased risk of SARS-CoV-2 infection. Multivariate analyses revealed that biologics were not associated with a significant increased risk of moderate-severe COVID-19, nor with the composite endpoint of moderate-severe COVID-19 or all-cause mortality within 90 days. Chronic systemic corticosteroids use was associated with significant increased risk of all tested outcome. Recent (within the prior 120 days) systemic corticosteroids use, but not former use, was significantly associated with increased risk of both moderate-severe COVID-19 and the composite of moderate-severe COVID-19 or all-cause mortality. Conclusion Biologics approved for asthma and systemic corticosteroids are not associated with increased risk of SARS-CoV-2 infection. By contrast, systemic corticosteroids are independent risk factor for worst COVID-19 severity and all-cause mortality. Our findings underscore the risk of recent or current exposure to systemic corticosteroids in asthmatics infected with SARS-CoV-2.

Several respiratory viral infections such as rhinovirus or influenza virus are definite risk factors for acute asthma exacerbations 1, 2 . Intriguingly, recent epidemiological studies suggest that patients with asthma are not at increased risk of exacerbations when infected with severe acute respiratory syndrome coronavirus 2 (SARS- and that asthmatics are not more susceptible to coronavirus disease 2019 or to the development of severe COVID-19 [3] [4] [5] [6] [7] . The management of COVID-19 in severe asthma remains challenging and it is unclear if patients with severe asthma could be at higher risk of worst outcomes at least in part because of safety concerns associated with therapies such as biologics or systemic corticosteroids (SCS) [8] [9] [10] [11] [12] [13] [14] .

Previous studies have suggested that the use of biologics for severe allergic and eosinophilic asthma were not associated with COVID-19 severity [13] [14] [15] , but the number of patients included in the studies was small. Furthermore, an association has been suggested between recent SCS use and poor outcomes in asthmatics with COVID-19 16 .

In the current study, we used a computerized database covering half of the Israeli population to evaluate the association between biologics or SCS use to PCR positivity for SARS-CoV-2 and COVID-19 severity and mortality among asthmatic patients.

This study is based on data from the computerized database of Clalit Health Services which provides inclusive health care for more than half of the Israeli population (~4.6 million). Health care coverage in Israel is mandatory according to the National Health Insurance Law and is provided by four groups akin to not-for-profit health maintenance organizations. All members of the different health maintenance organizations have a similar health insurance plan and similar access to health services, including low medications copayment. The electronic medical records of Clalit Health Services include data from multiple sources: records of primary care physicians, community specialty clinics, hospitalizations, laboratories, and pharmacies. A registry of chronic diseases diagnoses is compiled from these data sources. Diagnoses are captured in the registry by diagnosis-specific algorithms, employing International Classification of Diseases Ninth revision (ICD-9) code J o u r n a l P r e -p r o o f reading, text reading, laboratory test results and disease-specific drug usage. The first record of each data source is kept in the database, and the earliest recorded date, from any source, is used to define the starting date of the diagnosis. Several high-qualities, population-based studies have been conducted based on data retrieved from Clalit Health Services database [17] [18] .

Since the start of the COVID-19 pandemic, the Israeli Ministry of Health (MOH) has been collecting all COVID-19 related data and activities to a national database.

Among these activities are active surveillance for all laboratory-confirmed SARS-CoV-2 infections with mandatory daily reporting of PCR results, active surveillance of COVID-19-associated hospitalizations by daily updates from all hospitals, including daily status definitions during hospitalization. The collected data are transferred daily to the healthcare providers.

We used the computerized database of Clalit Health Services to retrospectively identify all adult (≥18 years) asthmatic patients (ICD-9, 493.xx) who underwent PCR testing for SARS-CoV-2 between 1st of March 2020 and 7th December 2020.

Identified patients served to assess the association between biologics or SCS use and PCR positivity for SARS-CoV-2, using case-control study approach where positive PCR patients constituted the cases and negative PCR patients constituted the control group. In addition, a cohort approach was used to assess the association between biologics or SCS use and COVID-19 severity, among patients with positive PCR for SARS-CoV-2 ( Figure E1 )

PCR tests for SARS-CoV-2 are obtained from nasopharyngeal swabs. PCR testing is offered free of charge for all the population without a need for referral.

Biologics or SCS use were determined based on Clalit Health Services pharmacy records using the Anatomical Therapeutic Chemical (ATC) classification codes. The following biologics approved for asthma were included: benralizumab (antiinterleukin 5 receptor monoclonal antibody), dupilumab (anti-interleukin 4 receptor alpha chain), mepolizumab (anti-interleukin 5), omalizumab (anti-immunoglobulin E), and reslizumab (anti-interleukin 5). A patient was defined as biologics user if he filled at least one prescription in the 120 days prior to PCR test. The number and the timing of SCS prescriptions filled in the prior year was used to examine the SCS J o u r n a l P r e -p r o o f exposure, using different definitions, i) users versus nonusers in the prior year, ii) number of prescriptions in the prior year (none vs.1 vs.2 vs. ≥3 prescriptions), iii) timing of SCS prescriptions filled in the prior year (none vs. recent ≤120 days vs.

former 120-365 days), and iv) chronic SCS use defined as purchasing ≥6 prescriptions in the prior year.

The association of biologics or SCS was assessed with the following outcomes, i) PCR positivity among asthmatic patients who were tested for SARS-CoV-2, ii) 90day all-cause mortality, iii) moderate-severe COVID-19 as defined on the Israeli Ministry of Health's guidelines, which are in accordance with the WHO definitions 19 and iv) composite of moderate-severe COVID-19 or 90-day all-cause mortality.

In addition, for each patient the following baseline data were retrieved from the computerized database of the Clalit Health Services: demographic and other descriptive variables, smoking status (smoker, never smoker), presence of selected chronic medical conditions including diabetes, hypertension, obesity, and ischemic heart disease.

Statistical analyses were performed using IBM SPSS Statistics 24.0 (IBM, New York, NY). For all analyses, P < 0.05 for the 2-tailed tests was considered statistically significant. Continuous variables were summarized with means and standard deviations (SD), and categorical variables were summarized with counts and proportions. Comparisons of baseline characteristics between patients with positive PCR and patients with negative PCR, and between patients on biologics and patients without biologics, were performed using the chi-square test for categorical variables and using the independent samples student t test for continuous variable.

Logistic regression models were used to examine the association between biologics or SCS use and PCR positivity among asthmatic patients who underwent PCR testing for SARS-CoV-2. Cox proportional hazard regression models were used to assess the association between recent biologics use or SCS use, among PCR positive patients, and each of the following outcomes; i) moderate-severe COVID-19, ii) 90-day allcause mortality, and iii) the composite of moderate-severe COVID-19 or 90-day allcause mortality. To examine the independent association of biologics and SCS use, the multivariate regression models were adjusted for; age, sex, ethnicity, diabetes, hypertension, ischemic heart disease, obesity, and smoking. Time to event was defined as the time that elapsed from the date of positive PCR test (date of cohort J o u r n a l P r e -p r o o f entry) until the first occurrence of study outcomes, death, or end of follow-up, whichever came first. Multivariate Cox regression models were used to depict the adjusted cumulative incidence curves of the study outcomes. An interaction between biologics and SCS use was tested by including an interaction factor of both variables into the multivariate Cox regression model.

Overall, 80,602 adults asthmatics (age ≥18 years) underwent PCR testing for SARS- Table E1 . Asthmatics who tested positive for SARS-CoV-2 were more likely to be younger, female, of an Arabic origin, and with significantly higher prevalence of obesity and diabetes, as compared to those who tested negative. No significant differences in SCS and biologics use were found between the two groups.

Only 464 (0.6%) of negative PCR patients and 50 (0.6%) of positive PCR patients were biologics users. The distribution of the different types of biologics was similar in both groups, with omalizumab being the most frequently used, followed by mepolizumab, benralizumab, dupilumab, and reslizumab (Table E1 ).

Biologics and SCS use were not associated with an increased risk of infection with SARS-CoV-2 in multivariate analyses; adjusted OR 0.99 (95% CI, 0.73-1.33) for biologics use and 0.96 (0.90-1.03) for SCS use, as compared to no use (Table E2 and   Table E3 ).

The second phase of the analysis was restricted to the 8,242 adult asthmatic patients with positive PCR for SARS-CoV-2 and aimed to assess the association of biologics use or SCS and outcomes. The baseline characteristics of biologics users (n=50) and nonusers (n=8192) are reported in Table 1 . Patients on biologics were older, mainly female with significantly higher prevalence of diabetes, obesity and hypertension and significantly higher use of SCS (Table 1 ). Blood eosinophils count was available in J o u r n a l P r e -p r o o f 90% of biologics users. Among anti-IL-5 users the mean absolute eosinophils count was 42/µL ± 39.

Multivariate analyses revealed that biologics use was not associated with a significant increased risk of moderate-severe COVID-19; adjusted HR 1.28 (0.60-2.73) ( Table   2) , nor with the composite endpoint of moderate-severe COVID-19 or all-cause mortality within 90 days; adjusted HR 1.42 (0.70-2.88) ( Table 3) , or all-cause mortality within 90 days; adjusted HR 1.04 (0.14-7.59) ( Table E4 ). The adjusted cumulative incidence curves of the composite endpoint are depicted, by biologics use status, in Figure E2a . No significant interaction was found between biologics use and SCS use on their association with the study outcomes. The adjusted HRs for the association of biologics use and study outcomes among SCS users was as follows; The number of filled SCS prescriptions in the previous year was associated with a statistically significant dose-response increase in the risk of tested outcomes ( Table 2, 3, E4 and Figure1). The adjusted cumulative incidence curves of the composite endpoint are depicted, by the number of filled SCS prescriptions, in Figure E2b .

Chronic SCS use was associated with significant increased risk of all tested outcome: The independent association of the other covariates with the examined outcomes is shown in Tables 2, 3 , and E4, E6-E11. In general, male sex, Arabic origin, diabetes, hypertension, obesity, and ischemic heart disease, were all significantly associated J o u r n a l P r e -p r o o f with increased risk of moderate-severe COVID-19 and the composite of COVID-19 severity or all-cause mortality (Tables 2 and 3 and E6-E11).

Whether biologic therapies approved for severe allergic and eosinophilic asthma are risk factors for poor COVID-19 outcomes is still debated 20 reported an increased risk of death from COVID-19 among people with asthma prescribed high-dose inhaled corticosteroids, however, various sensitivity analyses indicated that this increased mortality risk could be explained by unmeasured confounders. In contrast, a large multicenter prospective cohort study by Bloom et al 28 reported that patients with severe asthma were significantly more likely than those with no underlying respiratory condition to receive critical care and ventilatory support even after adjusting for severity on admission, age, and comorbidities.

Interestingly, the use of inhaled corticosteroids in patients aged 50 years and older within 2 weeks of admission was associated with decreased mortality. Other studies did not provide clear evidence of increased risk of COVID-19 severity, hospitalization, or mortality in asthmatics [29] [30] [31] Our large nationwide study of 80,602 adult asthmatics shows that patients treated with biologics or SCS are not at higher risk of SARS-CoV-2 infection. In addition, there was no significant risk of moderate-severe COVID-19 and mortality in severe asthmatics treated with biologics, when compared to those not receiving biologics. By contrast, SCS use was an independent risk factor for worst COVID-19 severity and all-cause mortality. Therefore, our findings underscore the risk of recent or chronic SCS use in asthmatics infected with SARS-CoV-2.

Two recent studies had suggested a higher susceptibility of SARS-CoV-2 infection in asthmatics, when compared to the general population, especially in those with severe asthma on biologic therapy 15, 32 . By contrast, data from the Belgian severe asthma Registry reported a relatively low incidence of COVID -19 in patients with severe asthma and no association with a higher risk of SARS-CoV-2 infection 13 . Moreover, asthmatics were not overrepresented in a cohort of consecutive patients with severe pneumonia due to SARS-CoV-2 infection who required hospitalization during the Spring 2020 outbreak in Paris 14 . Our study shows that severe asthmatics treated with biologic therapies for severe allergic and eosinophilic asthma, are not more likely to be infected with SARS-CoV-2, as compared to asthmatics who were not treated with biologics. Importantly in our study all cases of COVID-19 were diagnosed by positive PCR for SARS-CoV-2, while others included patients with COVID-19 diagnosis based on either PCR or clinical and/or radiological parameters 13, 14 .

COVID-19 severity and mortality are highly dependent on age and comorbidities, while asthma was not found to be an independent risk factor for severe COVID-19 or worst outcome [3] [4] [5] [6] [7] . Interestingly, although viral respiratory tract infections are an important cause of asthma exacerbations, it appears that SARS-CoV-2 infection is not associated with asthma exacerbation 13, 14 . In the Belgian severe asthma Registry, biologic therapy for severe allergic or eosinophilic asthma was not associated with COVID-19 severity 13 . In addition, Izquierdo et al 15 reported that COVID-19-related hospital admission was low among asthmatics treated by biologics in a large Spanish database. Interestingly, a retrospective study by Ferastraoaru and colleagues has suggested that pre-existing eosinophil count ≥150/μL was protective from future COVID-19-associated hospitalization, and that development of eosinophil count ≥150 /μL during hospitalization was associated with decreased mortality in a cohort of J o u r n a l P r e -p r o o f asthma patients with COVID-19 32 . However, this may not apply to patients treated biologics; indeed, in our study a significantly lower eosinophils count (42/µL ± 39) was not found to be associated with increased COVID-19 severity and mortality in patients treated with anti-IL-5. While our data are reassuring, additional analyses of higher number of patients on biologics are needed to definitively conclude on the lack of risk associated with the use of biologics in severe asthmatics infected with SARS-CoV-2.

By contrast, our study underscores the risk of recent or current exposure to SCS in asthmatics infected with SARS-CoV-2. Indeed, SCS use decreases innate and acquired immunity and predisposes to infection. Therefore, it is recommended to avoid chronic or repeated SCS whenever possible, and to prescribe the lowest possible dose of SCS in the subgroup of severe asthmatics requiring long-term treatment with oral corticosteroids 33 . A major finding of our study is that SCS treatment whether chronic or recent (defined as within 120 days before being infected with SARS-CoV-2), is associated with increased COVID-19 severity and 90-day mortality. Furthermore, COVID-19 severity and 90-day mortality increased in a dose response manner with the number of SCS prescription in the prior year (Figure 1 and Figure E2b ). Conversely, SCS use did not increase the likelihood of being infected with SARS-CoV-2. Other studies have also reported that recent SCS use in asthmatic patients was associated with increased COVID-19 mortality 16 . Therefore, severe asthmatics treated with chronic or recurrent SCS therapy to treat and/or prevent exacerbations and improve asthma control are at increased risk for severe COVID-19 and worst outcomes. Our results emphasize the need for optimized management of asthmatics in order to achieve asthma control and avoid whenever possible the need for chronic or recurrent use of SCS. In patients with severe uncontrolled asthma requiring chronic or recurrent use of SCS, steroid-sparing approaches are desirable alternatives. These include interventional and medical options, such as biologics in eligible allergic and/or eosinophilic patients. Our data suggest that these treatments may help achieving asthma control and by inference prevent worst outcomes when patients are infected with SARS-CoV-2.

In summary, biological treatment for severe allergic and eosinophilic asthma does not increase the risk of being infected with SARS-CoV-2 or COVID-19 severity. Chronic or recurrent use of SCS before SARS-CoV-2 infection is a major risk factor of poor outcomes and worst survival in asthmatics. We conclude that treating physicians *biologics use was defined as the documentation of filling at least one prescription of omalizumab, benralizumab, mepolizumab, reslizumab, or dupilumab in the 120 days prior to the positive PCR date. J o u r n a l P r e -p r o o f Tables 3, E7 , E9, E11 These patients were used to assess the association between biologics use and PCR positivity for SARS-CoV-2 using case-control approach: Cases: 8,242 with positive PCR Controls: 72,360 with negative PCR.

These patients were included in a cohort study to assess the association between biologics use and severity of COVID 

Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma

Role of viral respiratory infections in asthma and asthma exacerbations

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Reply to: inhaled corticosteroids and COVID-19

Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control & Prevention

Association of asthma and its genetic predisposition with the risk of severe COVID-19

Susceptibility in Bronchial Asthma

The Impact of Asthma on Mortality in Patients With COVID-19

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

The impact of COVID-19 on patients with asthma

Factors associated with COVID-19-related death using OpenSAFELY

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

Association of diabetes and glycated hemoglobin with the risk of intracerebral hemorrhage: a population-based cohort study

Clinical management of COVID-19 World Health Organization

COVID-19, asthma, and biological therapies: What we need to know

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study

Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Asthma in Adult Patients with COVID-19: Prevalence and Risk of Severe Disease Am J Respir Crit Care Med

Asthma among hospitalized patients with COVID-19 and related outcomes

*adjusted for age, sex, ethnicity, diabetes, hypertension, ischemic heart disease (IHD), obesity, smoking, steroids and biologics use